What is the company's revenue growth trend and what are the key drivers?

Stryker experienced robust revenue growth, with net sales increasing 15% to $1.63 billion in the first quarter of 2008 compared to the same period in 2007. This growth was primarily driven by increased unit volumes across both its Orthopaedic Implants and MedSurg Equipment segments, with a notable 17% increase in international sales. Favorable foreign currency exchange rates also contributed positively to reported sales.

How is the company's profitability trending?

Profitability has improved significantly. Net earnings from continuing operations increased by 20.1% to $290.5 million. This led to an increase in diluted earnings per share from continuing operations to $0.70, up from $0.58 in the first quarter of 2007, indicating effective cost management and operational leverage.

What are the main risks or potential headwinds the company is facing?

Stryker is managing several risks, including regulatory scrutiny, such as FDA warning letters related to manufacturing quality systems at certain facilities. They are also cooperating with the DOJ and SEC regarding potential Foreign Corrupt Practices Act violations. Additionally, the company holds Auction Rate Securities (ARS) where auctions have failed due to market liquidity issues; while management believes this won't impact operations, it limits immediate liquidity for these investments. A recall of Trident hip cups also impacted sales in that product line.

How is the company's balance sheet positioned, particularly regarding liquidity and investments?

The company maintains a strong balance sheet with $423.5 million in cash and cash equivalents and $1.94 billion in marketable securities at March 31, 2008. While the company has encountered liquidity issues with its Auction Rate Securities (ARS), which are now classified as non-current, management believes its overall liquidity and cash flow from operations are sufficient to meet its capital requirements, including investments, acquisitions, and share repurchases. The company also has significant available borrowing capacity.

SYK 10-Q Quarterly Report Q1 FY2008 — Revenue, Net Income, EPS

Summary

Stryker Corporation reported solid financial results for the first quarter of 2008, demonstrating robust top-line growth and improved profitability. Net sales increased by 15% year-over-year, driven by strong performance in both the Orthopaedic Implants and MedSurg Equipment segments. This growth was fueled by increased unit volumes and a favorable impact from foreign currency exchange rates. Net earnings from continuing operations saw a significant 20% increase, reflecting improved operating leverage and effective cost management. While the company navigates some regulatory and legal inquiries, including an FDA warning letter and ongoing cooperation with the DOJ and SEC regarding FCPA concerns, these appear to be managed within existing frameworks. A notable item is the continued impact of failed auctions for Auction Rate Securities (ARS), though management believes this will not impede ongoing operations. Overall, Stryker presents a strong financial picture with positive sales momentum and earnings growth, positioning it well for the remainder of 2008.

Key Highlights

1Stryker reported a 15% increase in net sales, reaching $1.63 billion for Q1 2008, driven by strong demand across both Orthopaedic Implants and MedSurg Equipment segments.
2Net earnings from continuing operations grew by 20.1% to $290.5 million, with diluted EPS from continuing operations rising to $0.70 from $0.58 in the prior year.
3International sales showed robust growth, increasing 17% year-over-year (5% on a constant currency basis), contributing significantly to overall revenue.
4The company maintained a strong financial position with $423.5 million in cash and cash equivalents and $1.94 billion in marketable securities at quarter-end.
5Despite a decline in hip implant sales (down 1% on a constant currency basis, influenced by a recall), other orthopaedic product lines like knee, trauma, spine, and craniomaxillofacial implants showed strong double-digit growth.
6The company is managing several regulatory matters, including FDA warning letters for quality systems and ongoing cooperation with the DOJ and SEC concerning potential FCPA violations.
7Stryker provided an optimistic outlook for 2008, projecting diluted EPS growth of approximately 22%.

STRYKER CORP Quarterly Report for Q1 Ended Mar 31, 2008

Summary

Key Highlights

Frequently Asked Questions